Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Talarico

Showing results (71-80 of 76) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 76 results.
AIDS (London, England)|July 14, 2021
Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatmentSusan Swindells, Thomas Lutz, Lelanie Van Zyl, et al.
The Lancet. HIV|October 14, 2021
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority studyHans Jaeger, Edgar T Overton, Gary Richmond, et al.
AIDS (London, England)|March 17, 2021
Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysisAmy G Cutrell, Jonathan M Schapiro, Carlo F Perno, et al.
The New England Journal of Medicine|March 5, 2020
Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 SuppressionSusan Swindells, Jaime-Federico Andrade-Villanueva, Gary J Richmond, et al.
International Angiology : a Journal of the International Union of Angiology|March 31, 2010
A consensus conference on complex biologics and low molecular weight heparinsE Kalodiki, J Fareed, V F Tapson, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 2, 2020
Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR TrialsGiuliano Rizzardini, Edgar T Overton, Chloe Orkin, et al.
Pageof 8

Showing results (71-80 of 76) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 76 results.
AIDS (London, England)|July 14, 2021
Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatmentSusan Swindells, Thomas Lutz, Lelanie Van Zyl, et al.
The Lancet. HIV|October 14, 2021
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority studyHans Jaeger, Edgar T Overton, Gary Richmond, et al.
AIDS (London, England)|March 17, 2021
Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysisAmy G Cutrell, Jonathan M Schapiro, Carlo F Perno, et al.
The New England Journal of Medicine|March 5, 2020
Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 SuppressionSusan Swindells, Jaime-Federico Andrade-Villanueva, Gary J Richmond, et al.
International Angiology : a Journal of the International Union of Angiology|March 31, 2010
A consensus conference on complex biologics and low molecular weight heparinsE Kalodiki, J Fareed, V F Tapson, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 2, 2020
Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR TrialsGiuliano Rizzardini, Edgar T Overton, Chloe Orkin, et al.
Pageof 8